Difference between revisions of "Autoimmune cytopenia"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
m (Text replacement - "|NR" to "|Not reported")
 
(51 intermediate revisions by 4 users not shown)
Line 1: Line 1:
−
{|style="width: 100%; border-left:solid 20px #dc143c;border-right:solid 20px #dc143c;border-top:solid 20px #dc143c;border-bottom:solid 20px #dc143c;" align="center"
+
<span id="BackToTop"></span>
−
|
+
<div class="noprint" style="background-color:LightGray; position:fixed; bottom:2%; right:0.25%; padding-left:5px; padding-right:5px; margin: 15px; opacity:0.8; border-style: solid; border-color:DarkGray; border-width: 1px">
−
<span style="font-family:Arial; font-size:200%">&nbsp;Hello!<br>
+
[[#top|Back to Top]]
−
&nbsp;We're happy that you've chosen to use HemOnc.org, and hope that you will return often. From now until January 31, we are conducting a survey to learn more about our users and how we can make the site better and more useful.<br>
+
</div>
−
&nbsp;Please help us by filling it out!<br>
+
{{#lst:Editorial board transclusions|heme}}
−
&nbsp;'''Link:''' http://j.mp/2BlBaoQ
+
''This is an umbrella category that includes Felty's syndrome (autoimmune neutropenia), [[#Autoimmune_thrombocytopenic_purpura_(ITP)|autoimmune thrombocytopenia (ITP)]], [[autoimmune hemolytic anemia (AIHA)]], and Evan's syndrome (AIHA & ITP). Please see the respective page(s) for disease-specific therapies. This page includes regimens that were used more broadly.''
−
</span>
+
*''We have moved [[How I Treat]] articles to a dedicated page.''
−
|}<br>'''Use of this site is subject to you reading and agreeing with the terms set forth in the [[HemOnc.org_-_A_Hematology_Oncology_Wiki:General_disclaimer|disclaimer]]. If this is your first time visiting, we suggest you read the [[tutorial]].''' 
 
−
 
 
−
Is there a regimen missing from this list?  Would you like to share a different dosage/schedule or an additional reference for a regimen?  Have you noticed an error?  Do you have an idea that will help the site grow to better meet your needs and the needs of many others?  You are [[How_to_contribute|invited to contribute to the site]].
 
−
{| class="wikitable" style="text-align:center; width:100%;"
 
−
!colspan="4" align="center" style="color:white; font-size:125%; background-color:#31a354"|'''Section editors'''
 
−
|-
 
−
|style="background-color:#F0F0F0; width:15%"|[[File:Shruti.jpg|frameless|upright=0.3|center]]
 
−
|style="width:35%"|<big>[[User:Shrutichaturvedi|Shruti Chaturvedi, MD, MSCI]]<br>Baltimore, MD</big><br>[https://www.linkedin.com/in/shruti-chaturvedi-bb83b126/ LinkedIn]
 
−
|style="background-color:#F0F0F0; width:15%"|[[File:Tillman_Benjamin-2.jpg|frameless|upright=0.3|center]]
 
−
|style="width:35%"|<big>[[User:Benjamintillman|Benjamin Tillman, MD]]<br>Nashville, TN</big>
 
−
|-
 
−
|}
 
 
{| class="wikitable" style="float:right; margin-right: 5px;"
 
{| class="wikitable" style="float:right; margin-right: 5px;"
 
|-
 
|-
−
|<div style="background-color: #66FF66; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}" align="right"><font size="4"><b>{{#ask: [[-Has subobject::{{FULLPAGENAME}}]] |?Regimen |limit=10000|format=sum}} regimens on this page</b></font></div>
+
|<div style="background-color: #fee0d1; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}" align="right"><font size="4"><b>{{#ask: [[-Has subobject::{{FULLPAGENAME}}]] |?Regimen |limit=10000|format=sum}} [[Tutorial#Regimens|regimens]] on this page</b></font></div>
−
<div style="background-color: #66CCFF; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}"><font size="4"><b>{{#ask: [[-Has subobject::{{FULLPAGENAME}}]] |?Variant |limit=10000|format=sum}} variants on this page</b></font></div>
+
<div style="background-color: #deebf6; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}"><font size="4"><b>{{#ask: [[-Has subobject::{{FULLPAGENAME}}]] |?Variant |limit=10000|format=sum}} [[Tutorial#Variants|variants]] on this page</b></font></div>
 
|}
 
|}
 
{{TOC limit|limit=3}}
 
{{TOC limit|limit=3}}
−
 
−
''This is an umbrella category that includes Felty's syndrome (autoimmune neutropenia), [[#Autoimmune_thrombocytopenic_purpura_(ITP)|autoimmune thrombocytopenia (ITP)]], autoimmune hemolytic anemia (AIHA), and Evan's syndrome (AIHA & ITP). Please see the respective page(s) for disease-specific therapies. This page includes regimens that were used more broadly.''
 
−
 
−
=Guidelines=
 
−
==British Society for Haematology==
 
−
*[http://onlinelibrary.wiley.com/doi/10.1111/bjh.14478/abstract The diagnosis and management of primary autoimmune haemolytic anaemia (2016)] [https://www.ncbi.nlm.nih.gov/pubmed/28005293 PubMed]
 
−
*[http://onlinelibrary.wiley.com/doi/10.1111/bjh.14654/abstract Guidelines on the management of drug-induced immune and secondary autoimmune, haemolytic anaemia (2017)] [https://www.ncbi.nlm.nih.gov/pubmed/28369704 PubMed]
 
−
 
 
=Relapsed or refractory=
 
=Relapsed or refractory=
−
 
 
==Alemtuzumab monotherapy {{#subobject:34416b|Regimen=1}}==
 
==Alemtuzumab monotherapy {{#subobject:34416b|Regimen=1}}==
−
{| class="wikitable" style="float:right; margin-left: 5px;"
+
<div class="toccolours" style="background-color:#eeeeee">
−
|-
 
−
|[[#top|back to top]]
 
−
|}
 
−
 
 
 
===Regimen {{#subobject:#30ab57|Variant=1}}===
 
===Regimen {{#subobject:#30ab57|Variant=1}}===
−
{| class="wikitable" style="width: 100%; text-align:center;"  
+
{| class="wikitable sortable" style="width: 80%; text-align:center;"  
−
!Study
+
!style="width: 25%"|Study
−
![[Levels_of_Evidence#Evidence|Evidence]]
+
!style="width: 25%"|Dates of enrollment
−
![[Levels_of_Evidence#Efficacy|Efficacy]]
+
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
 +
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
 
|-
 
|-
−
|[http://onlinelibrary.wiley.com/doi/10.1046/j.1365-2141.2001.03039.x/full Willis et al. 2001]
+
|[https://doi.org/10.1046/j.1365-2141.2001.03039.x Willis et al. 2001]
−
|style="background-color:#91cf61"|Phase II
+
|1995-11 to 2000-08
 +
|style="background-color:#91cf61"|Phase 2
 
|style="background-color:#b5b5b5"|ORR: 71%
 
|style="background-color:#b5b5b5"|ORR: 71%
 
|-
 
|-
 
|}
 
|}
 +
<div class="toccolours" style="background-color:#b3e2cd">
 
====Immunosuppressive therapy====
 
====Immunosuppressive therapy====
 
*[[Alemtuzumab (Campath)]] as follows:
 
*[[Alemtuzumab (Campath)]] as follows:
 
**Test dose: 1 mg IV over 60 minutes once
 
**Test dose: 1 mg IV over 60 minutes once
 
**Days 1 to 10: 10 mg IV over 4 hours once per day
 
**Days 1 to 10: 10 mg IV over 4 hours once per day
−
 
 
'''10-day course'''
 
'''10-day course'''
−
 
+
</div></div>
 
===References===
 
===References===
−
# Willis F, Marsh JC, Bevan DH, Killick SB, Lucas G, Griffiths R, Ouwehand W, Hale G, Waldmann H, Gordon-Smith EC. The effect of treatment with Campath-1H in patients with autoimmune cytopenias. Br J Haematol. 2001 Sep;114(4):891-8. [http://onlinelibrary.wiley.com/doi/10.1046/j.1365-2141.2001.03039.x/full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/11564082 PubMed]
+
# Willis F, Marsh JC, Bevan DH, Killick SB, Lucas G, Griffiths R, Ouwehand W, Hale G, Waldmann H, Gordon-Smith EC. The effect of treatment with Campath-1H in patients with autoimmune cytopenias. Br J Haematol. 2001 Sep;114(4):891-8. [https://doi.org/10.1046/j.1365-2141.2001.03039.x link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/11564082/ PubMed]
  
 
==Sirolimus monotherapy {{#subobject:35516b|Regimen=1}}==
 
==Sirolimus monotherapy {{#subobject:35516b|Regimen=1}}==
−
{| class="wikitable" style="float:right; margin-left: 5px;"
+
<div class="toccolours" style="background-color:#eeeeee">
−
|-
 
−
|[[#top|back to top]]
 
−
|}
 
−
 
 
 
===Regimen {{#subobject:#41ab57|Variant=1}}===
 
===Regimen {{#subobject:#41ab57|Variant=1}}===
−
{| class="wikitable" style="width: 100%; text-align:center;"  
+
{| class="wikitable sortable" style="width: 80%; text-align:center;"  
−
!Study
+
!style="width: 25%"|Study
−
![[Levels_of_Evidence#Evidence|Evidence]]
+
!style="width: 25%"|Dates of enrollment
 +
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
 +
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
 
|-
 
|-
 
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4705607/ Bride et al. 2015]
 
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4705607/ Bride et al. 2015]
−
|style="background-color:#91cf61"|Phase II
+
|Not reported
 +
|style="background-color:#91cf61"|Phase 2
 +
| style="background-color:#91cf60" |Durable CR observed in patients with ALPS
 
|-
 
|-
 
|}
 
|}
 +
<div class="toccolours" style="background-color:#b3e2cd">
 
====Immunosuppressive therapy====
 
====Immunosuppressive therapy====
−
*[[Sirolimus (Rapamune)]] 2 to 2.5 mg/m2/day PO
+
*[[Sirolimus (Rapamune)]] 2 to 2.5 mg/m<sup>2</sup>/day PO
−
**See manuscript for recommended dose adjustments
 
−
 
 
 
'''6-month course, extended for those with a favorable response'''
 
'''6-month course, extended for those with a favorable response'''
−
 
+
</div>
 +
<div class="toccolours" style="background-color:#fff2ae">
 +
====Dose and schedule modifications====
 +
*See manuscript for recommended dose adjustments
 +
</div></div>
 
===References===
 
===References===
−
# Bride KL, Vincent T, Smith-Whitley K, Lambert MP, Bleesing JJ, Seif AE, Manno CS, Casper J, Grupp SA, Teachey DT. Sirolimus is effective in relapsed/refractory autoimmune cytopenias: results of a prospective multi-institutional trial. Blood. 2016 Jan 7;127(1):17-28. Epub 2015 Oct 26. [http://www.bloodjournal.org/content/127/1/17.long link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4705607/ link to PMC article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/26504182 PubMed]
+
# Bride KL, Vincent T, Smith-Whitley K, Lambert MP, Bleesing JJ, Seif AE, Manno CS, Casper J, Grupp SA, Teachey DT. Sirolimus is effective in relapsed/refractory autoimmune cytopenias: results of a prospective multi-institutional trial. Blood. 2016 Jan 7;127(1):17-28. Epub 2015 Oct 26. [https://doi.org/10.1182/blood-2015-07-657981 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4705607/ link to PMC article] '''contains dosing details in abstract''' [https://pubmed.ncbi.nlm.nih.gov/26504182/ PubMed] [https://clinicaltrials.gov/study/NCT00392951 NCT00392951]
−
 
+
[[Category:Autoimmune cytopenia regimens]]
−
[[Category:Autoimmune cytopenias regimens]]
 
 
[[Category:Disease-specific pages]]
 
[[Category:Disease-specific pages]]
 
[[Category:Autoimmune hematologic conditions]]
 
[[Category:Autoimmune hematologic conditions]]
−
[[Category:Hemolytic disorders]]
+
[[Category:Hemolytic process]]
 
[[Category:Cytopenias]]
 
[[Category:Cytopenias]]

Latest revision as of 11:07, 6 July 2024

Back to Top

Section editor
Tillman Benjamin-2.jpg
 Benjamin Tillman, MD
Vanderbilt University
Nashville, TN, USA
LinkedIn

This is an umbrella category that includes Felty's syndrome (autoimmune neutropenia), autoimmune thrombocytopenia (ITP), autoimmune hemolytic anemia (AIHA), and Evan's syndrome (AIHA & ITP). Please see the respective page(s) for disease-specific therapies. This page includes regimens that were used more broadly.

  • We have moved How I Treat articles to a dedicated page.
2 regimens on this page
2 variants on this page


Relapsed or refractory

Alemtuzumab monotherapy

Regimen

Study Dates of enrollment Evidence Efficacy
Willis et al. 2001 1995-11 to 2000-08 Phase 2 ORR: 71%

Immunosuppressive therapy

  • Alemtuzumab (Campath) as follows:
    • Test dose: 1 mg IV over 60 minutes once
    • Days 1 to 10: 10 mg IV over 4 hours once per day

10-day course

References

  1. Willis F, Marsh JC, Bevan DH, Killick SB, Lucas G, Griffiths R, Ouwehand W, Hale G, Waldmann H, Gordon-Smith EC. The effect of treatment with Campath-1H in patients with autoimmune cytopenias. Br J Haematol. 2001 Sep;114(4):891-8. link to original article contains dosing details in manuscript PubMed

Sirolimus monotherapy

Regimen

Study Dates of enrollment Evidence Efficacy
Bride et al. 2015 Not reported Phase 2 Durable CR observed in patients with ALPS

Immunosuppressive therapy

6-month course, extended for those with a favorable response

Dose and schedule modifications

  • See manuscript for recommended dose adjustments

References

  1. Bride KL, Vincent T, Smith-Whitley K, Lambert MP, Bleesing JJ, Seif AE, Manno CS, Casper J, Grupp SA, Teachey DT. Sirolimus is effective in relapsed/refractory autoimmune cytopenias: results of a prospective multi-institutional trial. Blood. 2016 Jan 7;127(1):17-28. Epub 2015 Oct 26. link to original article link to PMC article contains dosing details in abstract PubMed NCT00392951
Retrieved from "https://hemonc.org/w/index.php?title=Autoimmune_cytopenia&oldid=88719"